Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Jane Street Group LLC trimmed its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 47.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 136,935 shares of the company’s stock after selling 123,146 shares during the period. Jane Street Group LLC owned approximately 0.11% of Atossa Therapeutics worth $208,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. Rhumbline Advisers purchased a new stake in Atossa Therapeutics in the 2nd quarter valued at about $161,000. Renaissance Technologies LLC lifted its position in Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after buying an additional 164,540 shares during the last quarter. XTX Topco Ltd purchased a new position in Atossa Therapeutics during the second quarter worth about $29,000. Finally, SG Americas Securities LLC increased its position in shares of Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after acquiring an additional 30,037 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on ATOS shares. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th. Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday, December 12th.

Atossa Therapeutics Stock Performance

Shares of ATOS opened at $0.90 on Monday. The company’s 50-day simple moving average is $1.18 and its 200-day simple moving average is $1.30. Atossa Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $2.31. The stock has a market capitalization of $113.69 million, a PE ratio of -4.11 and a beta of 1.26.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.